Oncology

The organizations give recommendations on how to get patients to receive the care they need.

FDA cleared cabozantinib (Cabometyx) for patients with advanced renal cell carcinoma as a first-line treatment in combination with nivolumab (Opdivo).

Deposing the ‘Emperor of All Maladies’ will take a diverse toolkit, not a single moonshot.

New treatment for metastatic HER2-positive breast cancer is called Margenza.

More oncologists are experiencing burnout due to the loss of face-to-face interactions with patients, according to a report from Cardinal Health Specialty Solutions.

Drug and diagnostic approvals and biosimilars news were popular with readers.

How the pandemic has accelerated innovation, and how CVS Health is preparing to delivery vaccines for COVID-19.

The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.

The second mRNA vaccine, which does not need the extreme refrigeration of the Pfizer product, began rolling out of a warehouse in Mississippi early Sunday. Friday brought other late-year approvals in cancer treatment.

Prostate cancer is often “indolent,” so it can be monitored and not treated right away.

After positive Phase 3 trial results, Karyopharm Therapeutics expects FDA to clear Xpovio.

A filing for a bispecific antibody, and more time after a therapy gets more responses.

The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Public health policies and treatment advances have made a difference.

Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.

Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.

In the early going, patients seeking the expensive, customized cancer treatments called CAR-T cell therapy had to go to an academic medical center. But that’s changing, as Duncan Allen, M.H.A., of the community cancer network OneOncology explains.

Two newly approved antibody-drug conjugates and changes in radiation therapy lead the way.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.

The Johns Hopkins professor and new MHE editorial advisory board member lauds the effects of the Affordable Care Act but holds out for a program that “gets every human being the healthcare that every human being deserves,” in this second part of a four-part series.

This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.